About Us
Revolutionary Therapies Designed for the Patient
Our Leadership Team
We are on a mission to transform the lives of people with allergic and autoimmune diseases by developing and delivering therapies that restore immune homeostasis to enhance efficacy, safety and convenience via patient friendly routes of administration. Revolo Biotherapeutics (“Revolo Bio”) has a global footprint, with headquarters in both Gaithersburg, MD, in the US, and London in the United Kingdom.
Our team of accomplished industry professionals has a track record of success in funding and executing drug development and commercialization plans. We are ready to revolutionize allergic and autoimmune disease treatment!
Executive Leadership Team

Jones W Bryan, ph.d.
President & Chief Executive Officer

Jonathan Gold
Chief Financial Officer

Dr. Roly Foulkes
Chief Scientific Officer

Kari Brown, m.d.
Chief Medical Officer
Senior Leadership Team

Beth Alley
Senior Vice President, Regulatory Affairs and Pipeline Planning

Femi Oluboyede
Vice President, Technical Operations, CMC

Jorge De Alba, ph.d.
Vice President, Discovery and Translational Science

Maria Pittaras, pmp
Vice President, Portfolio and Program Management

Paul Eggleton, ph.d.
Vice President, Immunology
Board of Directors

David Southwell
Chairman

Jones W Bryan, ph.d.
President & Chief Executive Officer

Peter Greenleaf
Non-Executive Director

Dr. Isaac Cheng
Non-Executive Director

Michael Albisser
Non-Executive Director

Marla S. Persky
Non-Executive Director

Glen Giovanetti
Non-Executive Director
